Team

Details

Prof. Andrew Hopkins FRSE FRSC - CEO Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery.

Prof. Andrew Hopkins FRSE FRSC - CEO
Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery.

Richard Bickerton PhD - CIO Richard completed his PhD from the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci. Prior to this he was a Senior Scientist at Inpharmatica, a London-based biotech for 5 years. In 2012 after joining the University of Dundee, Richard received the College of Life Sciences Innovator of the Year Award 2012.

Richard Bickerton PhD - CIO
Richard completed his PhD from the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci. Prior to this he was a Senior Scientist at Inpharmatica, a London-based biotech for 5 years. In 2012 after joining the University of Dundee, Richard received the College of Life Sciences Innovator of the Year Award 2012.

Andy Bell PhD FRSC -Chief Chemist Andy is one of the world’s leading medicinal chemists. He is a co-inventor of sildenafil and a contributor to the development of voriconazole. These medicines have generated sales of nearly $40 billion. With more than 30 years experience in the pharmaceutical industry, Andy was awarded the Technical Achievement Award in Organic Chemistry by the American Chemical Society, in recognition for his considerable contributions to medicinal chemistry.

Andy Bell PhD FRSC -Chief Chemist
Andy is one of the world’s leading medicinal chemists. He is a co-inventor of sildenafil and a contributor to the development of voriconazole. These medicines have generated sales of nearly $40 billion. With more than 30 years experience in the pharmaceutical industry, Andy was awarded the Technical Achievement Award in Organic Chemistry by the American Chemical Society, in recognition for his considerable contributions to medicinal chemistry.

Jérémy Besnard PhD - Chief Technology Officer Jérémy is a co-inventor of the original Exscientia technology for the Automated Design of ligands to Polypharmacological Profiles, which was developed during his PhD and published in Nature. Jérémy graduated with a French “Diplôme d’Ingénieur Chimiste” from The Ecole Nationale Superieure de Chimie de Montpellier and gained a MSc in Chemical Biology from the University of Montpellier II in 2008.

Jérémy Besnard PhD - Chief Technology Officer
Jérémy is a co-inventor of the original Exscientia technology for the Automated Design of ligands to Polypharmacological Profiles, which was developed during his PhD and published in Nature. Jérémy graduated with a French “Diplôme d’Ingénieur Chimiste” from The Ecole Nationale Superieure de Chimie de Montpellier and gained a MSc in Chemical Biology from the University of Montpellier II in 2008.

Mark Swindells PhD - COO Mark spent 7 years working in Japan at the Protein Engineering Research institute in Osaka, Yamanouchi Pharmaceutical Co. Ltd. (now Astellas) and Helix Research Institute . On returning to the UK he worked at Inpharmatica Ltd a biotechnology company focusing on knowledge-based drug discovery founded by Dame Prof Janet Thornton FRS.

Mark Swindells PhD - COO
Mark spent 7 years working in Japan at the Protein Engineering Research institute in Osaka, Yamanouchi Pharmaceutical Co. Ltd. (now Astellas) and Helix Research Institute . On returning to the UK he worked at Inpharmatica Ltd a biotechnology company focusing on knowledge-based drug discovery founded by Dame Prof Janet Thornton FRS.

Richard Cox MSc - Systems Architect After a degree in chemistry at Imperial College, Richard worked in various scientific research and consultancy roles at Thomson Scientific, Inpharmatica and Biovia (now Dassault Systèmes).

Richard Cox MSc - Systems Architect
After a degree in chemistry at Imperial College, Richard worked in various scientific research and consultancy roles at Thomson Scientific, Inpharmatica and Biovia (now Dassault Systèmes).

Heather Togwell BSc (Hons) - Project Manager Heather has over 20 years experience as Clinical Monitor and Project Manager in Clinical Research Trials Phases I - IV. She began her career in the CRO environment with 5 years at Quintiles, moving into mid-large Pharma, and has overseen numerous global and mega trials at Schering Plough, MSD, Pfizer and Novartis, across a variety of therapy areas including CNS, Women's Health, Oncology and Cardiovascular.

Heather Togwell BSc (Hons) - Project Manager

Heather has over 20 years experience as Clinical Monitor and Project Manager in Clinical Research Trials Phases I - IV. She began her career in the CRO environment with 5 years at Quintiles, moving into mid-large Pharma, and has overseen numerous global and mega trials at Schering Plough, MSD, Pfizer and Novartis, across a variety of therapy areas including CNS, Women's Health, Oncology and Cardiovascular.

Daniel Crowther DPhil - Head Target Analysis Daniel Is a bioinformatician with 20 years’ industry experience in Research and Translational informatics. After gaining his D. Phil from Oxford University, Daniel worked for 9 years at GSK.  He moved to Wyeth to help establish the Translational Medicine Research Collaboration and has recently spent 6 years in Frankfurt as a department head for Sanofi.

Daniel Crowther DPhil - Head Target Analysis

Daniel Is a bioinformatician with 20 years’ industry experience in Research and Translational informatics. After gaining his D. Phil from Oxford University, Daniel worked for 9 years at GSK.  He moved to Wyeth to help establish the Translational Medicine Research Collaboration and has recently spent 6 years in Frankfurt as a department head for Sanofi.

Willem van Hoorn PhD - Chemoinformatics Willem gained a PhD in computational chemistry in the group of David Reinhoudt at the University of Twente followed by a postdoc at Yale. He subsequently spent a decade at Pfizer focusing on computational techniques for HTS triage and combinatorial library design. This was followed by a position as senior solutions consultant at Accelrys assisting a range of clients from small biotech to big pharma.

Willem van Hoorn PhD - Chemoinformatics
Willem gained a PhD in computational chemistry in the group of David Reinhoudt at the University of Twente followed by a postdoc at Yale. He subsequently spent a decade at Pfizer focusing on computational techniques for HTS triage and combinatorial library design. This was followed by a position as senior solutions consultant at Accelrys assisting a range of clients from small biotech to big pharma.

Senga Oxenham PhD - Executive Officer After a career in research at the University of Dundee, first studing protein phosphorylation and then reproductive health, Senga moved into Project Management and Administration covering multiple international projects.

Senga Oxenham PhD - Executive Officer
After a career in research at the University of Dundee, first studing protein phosphorylation and then reproductive health, Senga moved into Project Management and Administration covering multiple international projects.

Adrian Scheyer PhD - Molecular Informatics Adrian is an interdisciplinary researcher with a broad background in computational approaches to drug discovery. He also holds a PhD from the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci. 

Adrian Scheyer PhD - Molecular Informatics
Adrian is an interdisciplinary researcher with a broad background in computational approaches to drug discovery. He also holds a PhD from the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci.